THERACARE MAXIMUM STRENGTH PAIN RELIEF 4% LIDOCAINE PATCH — Class II drug recall D-0065-2025
Terminated recall by Unexo Life Sciences Private Limited, reported 2024-12-04, distributed nationwide. cGMP Deviations
| Recall number | D-0065-2025 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Unexo Life Sciences Private Limited, New Delhi, India |
| Recall initiated | 2024-10-24 |
| Classified | 2024-11-22 |
| Reported by FDA | 2024-12-04 |
| Terminated | 2025-09-16 |
| Distributed | Nationwide (US) |
| Quantity | 455,536 patches |
| Reason classes | cgmp |
| UPC / GTIN / UDI-DI | 00845717008785, 00845717010566 |
| NDC | 71101-0001, 71101-0001-06, 71101-0001-24 |
Product
THERACARE MAXIMUM STRENGTH PAIN RELIEF 4% LIDOCAINE PATCH, a) 1 patch (NDC 71101-001-24, UPC 8 45717 00878 5) and b) 6 patches (NDC 71101-001-06, UPC 8 45717 01056 6), Manufactured for: Veridian Healthcare, LLC, Gurnee, IL 60031
Reason for recall
cGMP Deviations
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0065-2025. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.